There were n = 41 Selleckchem MEK162 esophageal adenocarcinomas (EAC) with associated Barrett’s esophagus (BE), n = 19 EAC without BE and n = 10 esophageal squamous-cell carcinomas (ESCC) of the esophagus (which were included as negative controls). EAC without BE was defined based on clinical information (endoscopic evidence of Barrett’s mucosa), work-up of all tumor blocks (specialized intestinal metaplasia) and Cdx-2 staining which is regarded

to have a 70% sensitivity [19]. Of note, EAC were tumors in the distal esophagus (AEG type I tumors, according to the classification by Siewert and Stein, 1998, Br J Surg [20]), and explicitly not localized at the level of the anatomic gastric cardia (AEG type II tumors). The AEG type II adenocarcinoma is a tumor entity on its own and must be discussed differently. GF120918 molecular weight Follow-up data were obtained from our local tumor registry of Lower Frankonia/Germany and was complete (100%) for all patients. In this tumor registry, data are stored also with permission obtained from the patients and due to the regulation of the local ethics committee. Mean follow-up was 29 months ± 17.6 standard deviation. Tumor and patient characteristics are summarized in Table 1 and 2. Table 1 Clinicopathological characteristics of

the EAC study population with BE Characteristics Patients (n = 41) LgR5 Barrett’s esophagus* p-value LgR5 Barrett’s selleck screening library EAC p-value     low high   low high   Age (y)       .100     .051 <66 21 (51%) 10 (48%) 11 (52%)  

4 (19%) 17 (81%)   ≥66 20 (49%) 4 (20%) 16 (80%)   10 (50%) 10 (50%)   Gender       .074     .673 Male 34 (83%) 14 (41%) 20 (59%)   11 (32%) 23 (68%)   Female 7 (17%) 0 (0%) 7 (100%)   3 (43%) 4 (57%)   Histological Grading       .305a     .083a G1 11 (27%) 6 (55%) 5 (45%)   6 (55%) 5 (45%)   G2 16 (39%) 5 (31%) 11 (69%)   6 (37%) 10 (63%)   G3/4 14(34%) 3 (21%) 11 (79%)   2 (14%) 12 (86%)   Depth of invasion Arachidonate 15-lipoxygenase       .481b     .155b pT1 10 (24%) 4 (40%) 6 (60%)   6 (60%) 4 (40%)   pT2 18 (44%) 7 (39%) 11 (61%)   6 (33%) 12 (67%)   pT3 6 (15%) 1 (17%) 5 (83%)   1 (17%) 5 (83%)   pT4 7 (17%) 2 (28%) 5 (72%)   1 (14%) 6 (86%)   Lymph node metastases       .001     .0154 pN0 15 (37%) 10 (67%) 5 (33%)   9 (60%) 6 (40%)   pN1-3 26 (63%) 4 (15%) 22 (85%)   5 (19%) 21 (81%)   UICC stage       .481c     .155c UICC I 9 (22%) 4 (44%) 5 (56%)   2 (22%) 4 (78%)   UICC II 19 (46%) 7 (37%) 12 (63%)   7 (37%) 12 (63%)   UICC III 13 (31%) 3 (23%) 10 (77%)   5 (15%) 11 (85%)   UICC IV 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%)   Median OS (m) 42 m 32 (n = 14) 24 (n = 27)   33 (n = 14) 28 (n = 27)   Abbrevations: EAC, esophageal adenocarcinomas; BE, Barrett metaplasia; y, years; G, grading; UICC, International Union against Cancer; R, residual tumor; OS, overall survival; m, months. *Clinico-pathological features of BE are related to adjacent EAC. aG1/2 vs. GT3/4; bpT1/2 vs. pT3/4; cUICC I/II vs.